Circulating cytokines allow for identification of malignant intraductal papillary mucinous neoplasms of the pancreas

被引:4
|
作者
Pu, Ning [1 ,2 ]
Chen, Qiangda [1 ,2 ]
Zhang, Jicheng [1 ,2 ]
Yin, Hanlin [1 ,2 ]
Wang, Dansong [1 ,2 ]
Ji, Yuan [2 ,3 ]
Rao, Shengxiang [4 ]
Kuang, Tiantao [1 ,2 ]
Xu, Xuefeng [1 ,2 ]
Wu, Wenchuan [1 ,2 ]
Lou, Wenhui [1 ,2 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, 180 Fenglin Rd, Shanghai 200032, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Dept Pathol, Shanghai, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Dept Radiol, Shanghai, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 04期
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
circulating cytokine score; intraductal papillary mucinous neoplasm; malignant transformation; nomogram; serum biomarker; INTERNATIONAL CONSENSUS GUIDELINES; SOLUBLE INTERLEUKIN-2-RECEPTOR; VALIDATION; RESECTION; NOMOGRAM; SURVIVAL; RISK; PREDICTION; MANAGEMENT; DYSPLASIA;
D O I
10.1002/cam4.5051
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Intraductal papillary mucinous neoplasms (IPMNs) are the precursor lesions of pancreatic cancers, requiring active surgical intervention during cancer development. However, the current criteria for predicting malignant IPMNs remain challenging and limited. Hence, this study aimed to assess the discriminatory performance of circulating cytokines, including TNF-alpha, IL-2R, IL-6, and IL-8, then build a novel predictive model to improve the diagnostic accuracy. Method A total of 131 retrospective (from March 2016 to December 2019) and 53 prospective (from March 2020 to January 2021) patients who were histologically confirmed as IPMNs were consecutively collected and analyzed. Result The circulating levels of TNF-alpha, IL-2R, IL-6, and IL-8 were significantly elevated in malignant IPMNs, and were verified as independent factors for malignant IPMNs (p < 0.05). Then, a novel score, the circulating cytokine score (CCS), was calculated and demonstrated as an independent predictive indicator with a higher area under the curve (AUC) than each cytokine alone (p < 0.001). Besides the CCS, two high-risk stigmata features, the presence of solid component (PSC), and main pancreatic duct (MPD) dilation >= 10 mm were also demonstrated as independent indicators for predicting malignant IPMNs. Finally, a novel nomogram incorporating the CCS and these two high-risk stigmata features presented a remarkable diagnostic performance, both in the training and validation cohorts with AUCs of 0.928 and 0.873, respectively. Conclusion The CCS can be considered a novel independent predictive indicator for malignant IPMNs. Additionally, the formulated nomogram model integrating the CCS, PSC, and MPD >= 10 mm can be a valuable and promising tool for predicting the malignant transformation of IPMNs during long-term follow-ups to assist in timely and accurate surgical decisions.
引用
收藏
页码:3919 / 3930
页数:12
相关论文
共 50 条
  • [41] Surgical Outcome of Intraductal Papillary Mucinous Neoplasms of the Pancreas
    Toshio Nakagohri
    Taira Kinoshita
    Masaru Konishi
    Shinichiro Takahashi
    Naoto Gotohda
    Annals of Surgical Oncology, 2007, 14 : 3174 - 3180
  • [42] Pathology and Classification of intraductal papillary mucinous Neoplasms of the Pancreas
    Schlitter, A. M.
    Esposito, I.
    CHIRURG, 2012, 83 (02): : 110 - +
  • [43] Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas
    Fujii, Tsutomu
    Kato, Koichi
    Kodera, Yasuhiro
    Kanda, Mitsuro
    Nagai, Shunji
    Yamada, Suguru
    Kanzaki, Akiyuki
    Sugimoto, Hiroyuki
    Nomoto, Shuji
    Takeda, Shin
    Morita, Satoshi
    Nakamura, Shigeo
    Nakao, Akimasa
    SURGERY, 2010, 148 (02) : 285 - 290
  • [44] Surgical Aspects of Intraductal Papillary Mucinous Neoplasms of the Pancreas
    Olah, A.
    Kollar, D.
    CHIRURGIA, 2015, 110 (05) : 413 - 417
  • [45] Intraductal papillary mucinous neoplasms of the pancreas: Is the puzzle solved?
    Balsarkar D.
    Takahata S.
    Tanaka M.
    Indian Journal of Gastroenterology, 2013, 32 (4) : 213 - 221
  • [46] Outcomes of Surgery for Intraductal Papillary Mucinous Neoplasms of the Pancreas
    Yasuhiro Fujino
    Yasuyuki Suzuki
    Takuro Yoshikawa
    Tetsuo Ajiki
    Takashi Ueda
    Ippei Matsumoto
    Yoshikazu Kuroda
    World Journal of Surgery, 2006, 30 : 1909 - 1914
  • [47] Outcomes of nonresected main-duct intraductal papillary mucinous neoplasms of the pancreas
    Daude, Mathieu
    Muscari, Fabrice
    Buscail, Camille
    Carrere, Nicolas
    Otal, Philippe
    Selves, Janick
    Buscail, Louis
    Bournet, Barbara
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (09) : 2658 - 2667
  • [48] Intraductal Papillary Mucinous Neoplasms of The Pancreas: A Nationwide Registry-Based Study
    Aronsson, L.
    Andersson, B.
    Andersson, R.
    Tingstedt, B.
    Bratlie, S. O.
    Ansari, D.
    SCANDINAVIAN JOURNAL OF SURGERY, 2018, 107 (04) : 302 - 307
  • [49] Prediction of malignancy in main duct or mixed-type intraductal papillary mucinous neoplasms of the pancreas
    Jung, Hye-Sol
    Han, Youngmin
    Kang, Jae Seung
    Sohn, Heeju
    Lee, Mirang
    Lee, Kyung-Bun
    Kim, Hongbeom
    Kwon, Wooil
    Jang, Jin-Young
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2022, 29 (09) : 1014 - 1024
  • [50] Utility of Radiological Follow Up of Main-Duct Intraductal Papillary Mucinous Neoplasms and Mixed-Type Intraductal Papillary Mucinous Neoplasms
    Tzadok, Roie
    Kessner, Rivka
    Ritter, Einat
    Aizic, Asaf
    Yashar, Hila
    Lazar, Sapir
    Katz, Yuval
    Ronen-Amsalem, Zur
    Chernomorets, Arthur
    Shibolet, Oren
    Ben-Ami Shor, Dana
    BIOMEDICINES, 2024, 12 (07)